Rosuvastatin 5 mg
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Rosuvastatin 5 mg: Efficacy and Safety in Hyperlipidemia Management
Introduction to Rosuvastatin 5 mg
Rosuvastatin, a potent statin, is widely used to manage hyperlipidemia and reduce cardiovascular risk. The 5 mg dose of rosuvastatin has been extensively studied for its efficacy and safety in various patient populations, including those with hypertriglyceridemia, hypercholesterolemia, and type 2 diabetes mellitus.
Efficacy in Reducing Triglycerides and LDL Cholesterol
Rosuvastatin 5 mg has shown significant efficacy in reducing triglyceride (TG) levels in hypertriglyceridemic patients. In a study involving Japanese patients, rosuvastatin 5 mg reduced TG levels by 30.1%, comparable to higher doses of 10 mg and 20 mg, indicating no dose-related effect on TG reduction. Additionally, in type 2 diabetes patients with combined hyperlipidemia, rosuvastatin 5 mg reduced TG by 24.5% and LDL cholesterol by 40.7%.
Comparison with Other Statins
When compared to other statins, rosuvastatin 5 mg has demonstrated superior efficacy. In a study comparing rosuvastatin 5 mg with atorvastatin 10 mg, rosuvastatin achieved greater reductions in LDL cholesterol (41.9% vs. 36.4%) and total cholesterol. Similarly, rosuvastatin 5 mg was more effective than simvastatin 20 mg and pravastatin 20 mg in lowering LDL cholesterol and total cholesterol.
Achieving LDL-C Goals
Rosuvastatin 5 mg has been effective in helping patients achieve LDL-C goals. In a study comparing rosuvastatin 5 mg with atorvastatin 10 mg, 80.3% of patients in the rosuvastatin group reached their LDL-C goals compared to 67.3% in the atorvastatin group. This highlights the potential of rosuvastatin 5 mg in achieving target lipid levels in high-risk patients.
Safety and Tolerability
Rosuvastatin 5 mg is generally well-tolerated with a safety profile comparable to other statins. In a study involving type 2 diabetes patients, both 5 mg and 10 mg doses of rosuvastatin were well-tolerated, with minimal side effects. Another study reported that 89% of patients intolerant to other statins tolerated rosuvastatin 5 mg well, with no cases of myositis or rhabdomyolysis observed.
Impact on Arterial Stiffness and NAFLD
Rosuvastatin 5 mg has also shown benefits beyond lipid lowering. In patients with optimally controlled arterial hypertension, rosuvastatin 5 mg reduced arterial stiffness and central pulse pressure. However, higher doses (20-40 mg) were more effective in reducing non-alcoholic fatty liver disease (NAFLD).
Conclusion
Rosuvastatin 5 mg is a highly effective and well-tolerated option for managing hyperlipidemia, particularly in reducing triglycerides and LDL cholesterol. It compares favorably with other statins and helps a significant proportion of patients achieve their LDL-C goals. Its safety profile makes it a suitable choice for patients intolerant to other statins, and it offers additional benefits in reducing arterial stiffness and managing NAFLD.
Sources and full results
Most relevant research papers on this topic